Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Demand for pharmacies contribute to 52% of the total searches, vaccination centres 30%
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Subscribe To Our Newsletter & Stay Updated
